Online inquiry

IVTScrip™ mRNA-Human AFAP1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK14378MR)

This product GTTS-WK14378MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AFAP1 protein. This product can be used in Brush cell (Tuft cell)-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001134647.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 60312
UniProt ID Q8N556
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AFAP1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK14378MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18970MR IVTScrip™ mRNA-Human AKIRIN2, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AKIRIN2
GTTS-WK12504MR IVTScrip™ mRNA-Human ADAMTS5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADAMTS5
GTTS-WK1748MR IVTScrip™ mRNA-Human CD71, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD71
GTTS-WK17728MR IVTScrip™ mRNA-Human AHSP, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHSP
GTTS-WK10659MR IVTScrip™ mRNA-Human ACTG1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACTG1
GTTS-WK11220MR IVTScrip™ mRNA-Human ACD, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD
GTTS-WK12880MR IVTScrip™ mRNA-Human AFAP1L2, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AFAP1L2
GTTS-WK28005MR IVTScrip™ mRNA-Human ARHGDIB, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARHGDIB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW